Stephen K. Doberstein - Sep 19, 2023 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role: Director
Signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Stock symbol: FBRX
Transactions as of: Sep 19, 2023
Transactions value $: $0
Form type: 4
Date filed: 9/20/2023, 05:48 PM
Previous filing: Jun 2, 2022
Next filing: Aug 22, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FBRX	Stock Option (right to buy)	Award	$0	+25K		$0.00	25K	Sep 19, 2023	Common Stock	25K	$0.80	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023.

Content

Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023.